Review



potent stat6 inhibitor  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress potent stat6 inhibitor
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Potent Stat6 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 71 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13065056-42-7-2?v=MedChemExpress
    Average 95 stars, based on 71 article reviews
    potent stat6 inhibitor - by Bioz Stars, 2026-07
    95/100 stars

    Images

    1) Product Images from "JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis"

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    Journal: PLOS One

    doi: 10.1371/journal.pone.0341313

    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Figure Legend Snippet: THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Techniques Used: Expressing

    THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Figure Legend Snippet: THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Techniques Used: Incubation, Expressing, Western Blot

    Schematic illustration of the regulatory mechanism by which JMJD3 influences M2-like macrophage polarization and promotes breast cancer cell growth through the STAT6/IRF4 axis.
    Figure Legend Snippet: Schematic illustration of the regulatory mechanism by which JMJD3 influences M2-like macrophage polarization and promotes breast cancer cell growth through the STAT6/IRF4 axis.

    Techniques Used:



    Similar Products

    potent stat6 inhibitor  (MedChemExpress)
    95
    MedChemExpress potent stat6 inhibitor
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Potent Stat6 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13065056-42-7-2?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    potent stat6 inhibitor - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    anti phospho stat6 tyr641 rabbit monoclonal antibodies  (Huabio Inc)
    86
    Huabio Inc anti phospho stat6 tyr641 rabbit monoclonal antibodies
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Anti Phospho Stat6 Tyr641 Rabbit Monoclonal Antibodies, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pm42308796-72-2-9?v=Huabio+Inc
    Average 86 stars, based on 1 article reviews
    anti phospho stat6 tyr641 rabbit monoclonal antibodies - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    anti p stat6  (Huabio Inc)
    86
    Huabio Inc anti p stat6
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Anti P Stat6, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pm42308796-103-37-39?v=Huabio+Inc
    Average 86 stars, based on 1 article reviews
    anti p stat6 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    stat6  (Cell Marque)
    86
    Cell Marque stat6
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Stat6, supplied by Cell Marque, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pm42230517-40-68-71?v=Cell+Marque
    Average 86 stars, based on 1 article reviews
    stat6 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    stat6 activation  (Galectin Therapeutics)
    86
    Galectin Therapeutics stat6 activation
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Stat6 Activation, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13201123-24-12-0?v=Galectin+Therapeutics
    Average 86 stars, based on 1 article reviews
    stat6 activation - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    p stat6  (Wanleibio)
    86
    Wanleibio p stat6
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    P Stat6, supplied by Wanleibio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pm42050662-93-41-47?v=Wanleibio
    Average 86 stars, based on 1 article reviews
    p stat6 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    mouse phospho stat6  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc mouse phospho stat6
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Mouse Phospho Stat6, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13049607-338-66-69?v=Cell+Signaling+Technology+Inc
    Average 95 stars, based on 1 article reviews
    mouse phospho stat6 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti stat6  (Proteintech)
    95
    Proteintech rabbit polyclonal anti stat6
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Rabbit Polyclonal Anti Stat6, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13049607-9-0-4?v=Proteintech
    Average 95 stars, based on 1 article reviews
    rabbit polyclonal anti stat6 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    rabbit monoclonal anti phospho stat6 tyr641  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc rabbit monoclonal anti phospho stat6 tyr641
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Rabbit Monoclonal Anti Phospho Stat6 Tyr641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13049607-5-0-6?v=Cell+Signaling+Technology+Inc
    Average 86 stars, based on 1 article reviews
    rabbit monoclonal anti phospho stat6 tyr641 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    stat6  (Proteintech)
    95
    Proteintech stat6
    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, <t>p-STAT6-Y641,</t> and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.
    Stat6, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stat6+in/pmc13049607-338-63-64?v=Proteintech
    Average 95 stars, based on 1 article reviews
    stat6 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Article Snippet: AS1517499 (HY-100614, MCE) is a novel and potent STAT6 inhibitor.

    Techniques: Expressing

    THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

    Article Snippet: AS1517499 (HY-100614, MCE) is a novel and potent STAT6 inhibitor.

    Techniques: Incubation, Expressing, Western Blot

    Schematic illustration of the regulatory mechanism by which JMJD3 influences M2-like macrophage polarization and promotes breast cancer cell growth through the STAT6/IRF4 axis.

    Journal: PLOS One

    Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

    doi: 10.1371/journal.pone.0341313

    Figure Lengend Snippet: Schematic illustration of the regulatory mechanism by which JMJD3 influences M2-like macrophage polarization and promotes breast cancer cell growth through the STAT6/IRF4 axis.

    Article Snippet: AS1517499 (HY-100614, MCE) is a novel and potent STAT6 inhibitor.

    Techniques: